Lidofenin is ligand for a coordination complex consisting of the radioisotope technetium-99m. Technetium Lidofenin is a nontoxic radiopharmaceutical that is used in radionuclide imaging for the clinical evaluation of hepatobiliary disorders in humans. Technetium lidofenin is indicated as a hepatobiliary imaging agent for the evaluation of hepatobiliary tract patency to differentiate jaundice resulting from hepatocellular causes from jaundice resulting from partial or complete biliary obstruction; to differentiate extrahepatic biliary atresia from neonatal hepatitis; to detect cystic duct obstruction associated with acute cholecystitis nd to detect bile leaks. Also, technetium Tc 99m lidofenin may be useful to detect intrahepatic cholestasis and to distinguish it from other hepatobiliary diseases, which involve hepatocyte damage. Following intravenous administration, technetium Tc 99m–labeled IDA derivatives, such as lidofenin, become bound to plasma proteins (mainly albumin). In the liver, in the space of Disse, technetium Tc 99m lidofenin becomes dissociated from the proteins and enters the hepatocyte by a mechanism similar to that of serum bilirubin. Technetium Tc 99m lidofenin traverses through the hepatocyte unmetabolized and enters the bile canaliculi. Flow beyond the canaliculi is influenced to a large extent by the tone of the sphincter of Oddi and the patency of the bile ducts. Clear visualization of the gallbladder and intestines, usually within 15 to 30 minutes of administration, demonstrates hepatobiliary tract patency.